Companies and Nations Respond to the U.S.-U.K. Agreement to Eliminate Tariffs, Boost Drug Prices

And doing the math on 340B rebate models suggests that pharma’s new approach to paying 340B discounts shouldn’t harm providers

Brian Reid

Dec 4, 2025